# Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

> **NCT06793917** · PHASE3 · RECRUITING · sponsor: **Fujian Cancer Hospital** · enrollment: 269 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** Oxaliplatin injection
- **DRUG:** Levo-Leucovorin
- **DRUG:** 5-fluorouracil
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT06793917
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-07
- **Primary completion:** 2028-04-01
- **Final completion:** 2029-04-01
- **Target enrollment:** 269 (ESTIMATED)
- **Last updated:** 2025-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06793917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06793917, "Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06793917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*